Nanobiotix has presented complete outcomes from the dose escalation and dose expansion phases of the Phase I trial of ...

Janux Therapeutics has commenced Phase Ib expansion trials with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial.

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.

Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

Chengdu Origen and Vanotech have initiated the first subject dosing in the Phase I trial, VAN-2401, of KH658 for treating wet ...

OBI Pharma has received clearance from the US FDA for an IND application for OBI-902 to begin a Phase I/II trial for advanced ...

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

The FDA approved AstraZeneca's Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

BioCardia has announced the enrolment of the first subject in CardiAMP HF II trial of its cell therapy for treating heart ...

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...